Focusing on urologic oncology and education, Dr. Chang has led efforts in integration of evidence-based medicine in clinical pathways, enhanced guidelines formulation and improved cancer staging. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere.

As Chairman of the SUO Panel on Hormone Refractory Prostate Cancer and the Vice-Chair of the AUA Guidelines on Noninvasive Bladder Cancer, Dr. Chang successfully combined expert opinion with study results. As an AUA-EAU Academic Exchange Fellow, he further promoted critical evidentiary analysis and educational reforms. He currently serves as the Facilitator on the Renal Malignancy Follow-Up AUA Guidelines Panel and chairs the AUA Prostate Cancer Core Curriculum Committee. Dr. Chang is currently the chair of the American Joint Committee on Cancer (AJCC) GU Staging Task force and a member of the U.S. Committee on Cancer.

Earlier, his research verified PSMA antigenic expression in tumor neo-vasculature of multiple tumors. This work serves as the basis for ongoing research on targeted antibody diagnostic and therapeutic applications.

Dr. Chang has authored more than 200 original publications. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, the CaPCURE Young Investigator Award, and was named a Journal of Urology’s Best Reviewer.

Dr. Chang was recently named as the 2011 recipient of the prestigious American Urological Association Gold Cystoscope Award.